Logo image of IDP.DE

BIOGEN INC (IDP.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:IDP - US09062X1037 - Common Stock

155.9 EUR
+2.35 (+1.53%)
Last: 12/4/2025, 7:00:00 PM
Fundamental Rating

5

Overall IDP gets a fundamental rating of 5 out of 10. We evaluated IDP against 81 industry peers in the Biotechnology industry. While IDP has a great health rating, its profitability is only average at the moment. IDP has a bad growth rate and is valued cheaply. This makes IDP very considerable for value investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

In the past year IDP was profitable.
In the past year IDP had a positive cash flow from operations.
IDP had positive earnings in each of the past 5 years.
Each year in the past 5 years IDP had a positive operating cash flow.
IDP.DE Yearly Net Income VS EBIT VS OCF VS FCFIDP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

1.2 Ratios

IDP has a Return On Assets of 5.51%. This is in the better half of the industry: IDP outperforms 79.01% of its industry peers.
IDP has a Return On Equity of 8.84%. This is amongst the best in the industry. IDP outperforms 80.25% of its industry peers.
The Return On Invested Capital of IDP (9.70%) is better than 86.42% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IDP is below the industry average of 13.22%.
Industry RankSector Rank
ROA 5.51%
ROE 8.84%
ROIC 9.7%
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
IDP.DE Yearly ROA, ROE, ROICIDP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

With an excellent Profit Margin value of 15.98%, IDP belongs to the best of the industry, outperforming 81.48% of the companies in the same industry.
In the last couple of years the Profit Margin of IDP has declined.
IDP has a better Operating Margin (28.50%) than 87.65% of its industry peers.
IDP's Operating Margin has declined in the last couple of years.
IDP's Gross Margin of 75.24% is fine compared to the rest of the industry. IDP outperforms 65.43% of its industry peers.
IDP's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 28.5%
PM (TTM) 15.98%
GM 75.24%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
IDP.DE Yearly Profit, Operating, Gross MarginsIDP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IDP is creating some value.
Compared to 1 year ago, IDP has more shares outstanding
Compared to 5 years ago, IDP has less shares outstanding
The debt/assets ratio for IDP has been reduced compared to a year ago.
IDP.DE Yearly Shares OutstandingIDP.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
IDP.DE Yearly Total Debt VS Total AssetsIDP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

An Altman-Z score of 3.35 indicates that IDP is not in any danger for bankruptcy at the moment.
IDP's Altman-Z score of 3.35 is fine compared to the rest of the industry. IDP outperforms 72.84% of its industry peers.
IDP has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as IDP would need 2.78 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.78, IDP is in the better half of the industry, outperforming 79.01% of the companies in the same industry.
A Debt/Equity ratio of 0.35 indicates that IDP is not too dependend on debt financing.
IDP has a Debt to Equity ratio of 0.35. This is comparable to the rest of the industry: IDP outperforms 48.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 2.78
Altman-Z 3.35
ROIC/WACC1.18
WACC8.2%
IDP.DE Yearly LT Debt VS Equity VS FCFIDP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

IDP has a Current Ratio of 2.72. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.72, IDP is in line with its industry, outperforming 55.56% of the companies in the same industry.
IDP has a Quick Ratio of 2.04. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of IDP (2.04) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.72
Quick Ratio 2.04
IDP.DE Yearly Current Assets VS Current LiabilitesIDP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

3

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.51% over the past year.
Measured over the past years, IDP shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.31% on average per year.
Looking at the last year, IDP shows a small growth in Revenue. The Revenue has grown by 4.77% in the last year.
The Revenue has been decreasing by -7.62% on average over the past years.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%

3.2 Future

Based on estimates for the next years, IDP will show a small growth in Earnings Per Share. The EPS will grow by 0.56% on average per year.
IDP is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.63% yearly.
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.56%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.63%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IDP.DE Yearly Revenue VS EstimatesIDP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B
IDP.DE Yearly EPS VS EstimatesIDP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10 20 30

7

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 10.86, the valuation of IDP can be described as reasonable.
92.59% of the companies in the same industry are more expensive than IDP, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.41, IDP is valued rather cheaply.
IDP is valuated reasonably with a Price/Forward Earnings ratio of 11.65.
Based on the Price/Forward Earnings ratio, IDP is valued cheaper than 97.53% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.40, IDP is valued rather cheaply.
Industry RankSector Rank
PE 10.86
Fwd PE 11.65
IDP.DE Price Earnings VS Forward Price EarningsIDP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

87.65% of the companies in the same industry are more expensive than IDP, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 92.59% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 11.79
EV/EBITDA 7.98
IDP.DE Per share dataIDP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

IDP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%

0

5. Dividend

5.1 Amount

IDP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BIOGEN INC

FRA:IDP (12/4/2025, 7:00:00 PM)

155.9

+2.35 (+1.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-10 2026-02-10/amc
Inst Owners92.49%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap22.87B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.81
Price Target154.93 (-0.62%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)4.58%
PT rev (3m)5.78%
EPS NQ rev (1m)-53.66%
EPS NQ rev (3m)-54.42%
EPS NY rev (1m)-3.62%
EPS NY rev (3m)-4.16%
Revenue NQ rev (1m)-2.43%
Revenue NQ rev (3m)-2.17%
Revenue NY rev (1m)0.92%
Revenue NY rev (3m)0.95%
Valuation
Industry RankSector Rank
PE 10.86
Fwd PE 11.65
P/S 2.65
P/FCF 11.79
P/OCF 10.87
P/B 1.47
P/tB 11.19
EV/EBITDA 7.98
EPS(TTM)14.35
EY9.2%
EPS(NY)13.38
Fwd EY8.59%
FCF(TTM)13.22
FCFY8.48%
OCF(TTM)14.34
OCFY9.2%
SpS58.82
BVpS106.39
TBVpS13.94
PEG (NY)N/A
PEG (5Y)N/A
Graham Number185.34
Profitability
Industry RankSector Rank
ROA 5.51%
ROE 8.84%
ROCE 11.07%
ROIC 9.7%
ROICexc 11.44%
ROICexgc 40.96%
OM 28.5%
PM (TTM) 15.98%
GM 75.24%
FCFM 22.48%
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 2.78
Debt/EBITDA 1.73
Cap/Depr 25.04%
Cap/Sales 1.9%
Interest Coverage 250
Cash Conversion 67.56%
Profit Quality 140.63%
Current Ratio 2.72
Quick Ratio 2.04
Altman-Z 3.35
F-Score5
WACC8.2%
ROIC/WACC1.18
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.56%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.63%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year7.73%
EBIT Next 3Y2.84%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%

BIOGEN INC / IDP.DE FAQ

What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.


Can you provide the valuation status for BIOGEN INC?

ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.


What is the profitability of IDP stock?

BIOGEN INC (IDP.DE) has a profitability rating of 6 / 10.


Can you provide the financial health for IDP stock?

The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.


Can you provide the expected EPS growth for IDP stock?

The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -5.79% in the next year.